Delayed Common Post-operative complications occurred after LAAO Dr. Iat-Lon,Leong Department of Medicine, Division of Cardiology Macau Kiang Wu Hospital.

Slides:



Advertisements
Similar presentations
Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation.
Advertisements

ACTIVE Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Transcatheter LAA Occlusion
Percutaneous Closure of the Left Atrial Appendage versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomized.
NOAC but NICE Conference 16th July 2013.
Educational Event 23rd & 24th January 2013
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
ATRIAL FIBRILLATION.
Atrial Fibrillation Service
ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
AF and the New Oral Anti-Coagulants
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
WATCHMAN™ Left Atrial Appendage Closure Device
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Atrial fibrillation Cardiology #2 Gimadeeva A.D..
Protecting Against Stroke
Stroke prevention in atrial fibrillation
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
AF and NOACs An UPDATE JULY 2014
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Atrial Fibrillation Warfarin and its newer alternatives
Secondary prevention after a TIA or ischemic stroke.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Left atrial appendage occlusion: Ready for prime time? David Hildick-Smith Sussex Cardiac Centre Brighton, UK.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Update in ESC: Dabigatran among OAC
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Rikki Weems, PGY III August 20, 2015
Cardioembolic Stroke: Diagnosis and Management
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.
Anticoagulation in Atrial Fibrillation Dalia Hawwass PGY2 June 2015.
Net clinical benefit of OAC
R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
Rachel Neubrander, PhD Division of Cardiovascular Devices
LAAC: What Does the Post Marketing Data Tell Us?
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Cardiology Division, Jeju National University Hospital, Jeju, KOREA
Update on the Watchman Device CRT 2010 Washington, DC
LAAO with Watchman Device Post-Procedure Best Practices
Role of LAA Occlusion in Patients With Atrial Fibrillation After PCI Marco Mennuni, MD Interventional Cardiologist Hopital Europeen George Pompidou,
CRT 2017: Putting LAA closure in the age of DOACs into perspective
When should aspirin be dropped from triple therapy?
You can never be too Thin…. An Update on NOACs
How to Screen Patients for LAAC
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Polypharmacy Anticoagulation: AF meets PCI
Sameer Gafoor, MD Swedish Medical Center, Seattle WA
Anticoagulation in Atrial Fibrillation
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Randomized Evaluation of Long-term anticoagulant therapY
Click here for title Click here for subtitle
US Guidelines US Guidelines Low-risk Patients.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Nat. Rev. Cardiol. doi: /nrcardio
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Left atrial appendage closure: A new technique for clinical practice
5 Good Minutes on Atrial Fibrillation-related Stroke
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation  David R. Holmes, MD, Mohamad Alkhouli,
Erratum Canadian Journal of Cardiology
Figure 8. Stroke prevention strategy in patients with AF
Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure ADRIFT investigators.
Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure ADRIFT investigators.
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Delayed Common Post-operative complications occurred after LAAO Dr. Iat-Lon,Leong Department of Medicine, Division of Cardiology Macau Kiang Wu Hospital

Atrial Fibrillation Stroke prevention is an important Consideration. (1/3 Afib patients will suffer a stoke) Treatment with anticoagulant medications. The majority of embolic strokes originate from the left atrial appendage ( 90% of the clots form in the LAA) Left atrial appendage occlusion devices offer a non- pharmacologic alternative to anticoagulant medications.

Case Information Asian Gentleman 67 y.o PH: HBP & T2DM Holter : Paroxysmal atrial fibrillation and atrial flutter (2010) CHA 2 DS 2 -VASC Score :3

Case Information Anticoagulant medications Warfarin 3~3.5mg  Dabigatran 110mg BID Poor INR control Recurrent Side effect Petechiae 11/2010 Transient Ischemic Attack 2/2012 Hematuria 1/2014 Thalamus hemorrhage 4/2014 Stable after Conservative treatment

Case Information HAS-BLED Score: 4 HAS-BLED score: 4. The patient has a HIGH risk of bleeding (HAS-BLED score >/=3). The risk of major bleeding within 1 year in patients with atrial fibrillation enrolled in the Euro Heart Survey, expressed as bleeds per 100 patient years: 8.7%. Some caution and regular review of the patient is needed following the initiation of antithrombotic therapy, whether with oral anticoagulation or aspirin.

LAAO 2014/06/21 LAA Orifice diameter 21.6mm (TEE) 26mm Amplatzer Cardiac Plug was selected Smooth Procedure Angiography and TEE were performed Antithrombotic Therapy (Dual platelet inhibition) : ASA(100mg/d)+Clopidogrel(75mg/d) =4-6 weeks=> ASA(100mg/d) Good condition follow up at 7/2014

REFERENCELAA Orifice

TEE

IMPLATIONANGIOGRAPHY

Nightmare 22/7 was send to AED Complain : SOB, Abdominal pain and sweating for half hour BP:79/53mmHg, Pulse: 87bpm, SPO 2 : 95 % FAST test : Large pericardial effusion ◦ Pericardiocentesis : bloody drainage solution Continue to observation at ICU

Recurrent drainage of pericardial effusion 400~500 ml drainage Solution /1 st day 10~20ml drainage at follow time CT (23/7) : No Peri-device Leak, Mild pericardial effusion, No significant contrast extravasation

Treatment 1. Stop Antithrombotic Therapy 2. Pericardial drainage 3 Remove the drainage set 7 days later ECHO follow up : No significant pericardial effusion Patient discharged at 15/Aug Good Condition F/U at OPD

Question 1. Why was it happened 1 month after procedure? 2.Why did it occur so urgent in this event ? 3. Did it relate with antithrombotic therapy? 4. How is the follow up of this procedure?

LAA occlusion Complication ComplicationRATE Pericardial Effusion5% Stroke (Procedure-Related,No Procedure-Related)0.9% Device-associated thrombus4.2% Bleeding0.8% Vascular Complications0.8% Device Embolization0.6% V Reddy,et al Circulation,2011

Amplatzer Left Atrial Appendage Occlusion: Single Center 10-Year Experience 152 pts in Europe

ACP Post-Market EU observational Study

ACP Post-Market EU Observational Study

Antithrombotic Therapy First 6 weeks TEE ruled out thrombus and Peri-Device flow OAC, Dual Platelet Inhibition  ASA 100mg/d Antithrombotic Therapy Time Aspirin 100mg/d + Clopidogrel 75mg /d  Aspirn 100mg/d6 weeks Aspirin 100mg/d6 weeks Warfarin/NOAC (prexisting OAC)6 weeks

Conculsion: Cause of Pericardial Effusion is unknow Dual platelet inhibition?? No Guideline can be follow of the Antithrombotic Therapy (ASA? ASA + Clopidogrel? Warfarin?) Regular Follow up is necessary (TEE/CT/ECHO) Closely monitor at first month 6 week / 3 month / 6 month /1 yr

In the future More Trial to reduce the Probability of complications Recommendation of Antithrombotic Therapy Type and Duration

Thank you